Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs

MicroRNAs and other non-coding RNAs in adipose tissue and obesity: emerging roles as biomarkers and therapeutic targets

(2019) Silvia Lorente-Cebrián et al.   CLINICAL SCIENCE

MicroRNAs as Potential Pharmaco-targets in Ischemia-Reperfusion Injury Compounded by Diabetes

(2019) Hassan Dehaini et al.   Cells

High-throughput sequencing of small RNAs and analysis of differentially expressed microRNAs associated with high-fat diet-induced hepatic insulin resistance in mice

(2019) Xue Zhao et al.   Genes and Nutrition

microRNA Crosstalk Influences Epithelial-to-Mesenchymal, Endothelial-to-Mesenchymal, and Macrophage-to-Mesenchymal Transitions in the Kidney

(2019) Swayam Prakash Srivastava et al.   Frontiers in Pharmacology

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis

(2018) Swayam Prakash Srivastava et al.   Cell Death & Disease

Variations in MicroRNA-25 Expression Influence the Severity of Diabetic Kidney Disease

(2017) Yunshuang Liu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria

(2017) Feng-Yi Hsu et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis

(2017) Takahiro Uchida et al.   RENAL FAILURE

FGFR1 is critical for the anti-endothelial mesenchymal transition effect of N-acetyl-seryl-aspartyl-lysyl-proline via induction of the MAP4K4 pathway

(2017) Jinpeng Li et al.   Cell Death & Disease

MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy

(2017) Zhanmei Zhou et al.   Cell Death & Disease

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter?

(2016) Dimitris Mavridis et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1

(2016) Ha Won Lee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Olmesartan Prevents Microalbuminuria in db/db Diabetic Mice Through Inhibition of Angiotensin II/p38/SIRT1-Induced Podocyte Apoptosis

(2016) Junhui Gu et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Prolyl Oligopeptidase Inhibition Attenuates Steatosis in the L02 Human Liver Cell Line

(2016) Da Zhou et al.   PLoS One

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen

(2016) Kyoko Nitta et al.   Biomed Research International

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis

(2016) Swayam Prakash Srivastava et al.   Scientific Reports

Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition

(2015) Sen Shi et al.   KIDNEY INTERNATIONAL

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis

(2015) Suetonia C Palmer et al.   LANCET

Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen

(2014) Keizo Kanasaki et al.   DIABETES

Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction

(2014) Hye Sook Min et al.   LABORATORY INVESTIGATION

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition

(2014) Takako Nagai et al.   Biomed Research International

Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

(2013) Regina Kunz et al.   ANNALS OF INTERNAL MEDICINE

Physiology and pathophysiology of incretins in the kidney

(2013) Karoline von Websky et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

MicroRNA-29b Inhibits Diabetic Nephropathy in db/db Mice

(2013) Hai-Yong Chen et al.   MOLECULAR THERAPY

Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis

(2013) H.-Y. Wu et al.   BMJ-British Medical Journal

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT

(2013) Swayam Prakash Srivastava et al.   Biomed Research International

MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition

(2012) D. Macconi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function

(2012) Shetal H. Padia et al.   PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY

Comprehensive miRNome and in silico analyses identify the Wnt signaling pathway to be altered in the diabetic liver

(2011) Kirandeep Kaur et al.   Molecular BioSystems

Cellular and molecular mechanisms of renal fibrosis

(2011) Youhua Liu   Nature Reviews Nephrology

miR-200a Prevents Renal Fibrogenesis Through Repression of TGF- 2 Expression

(2010) B. Wang et al.   DIABETES

Angiotensin AT 2 Receptor Stimulation Inhibits Early Renal Inflammation in Renovascular Hypertension

(2010) Luis C. Matavelli et al.   HYPERTENSION

Loss of MicroRNA-192 Promotes Fibrogenesis in Diabetic Nephropathy

(2010) A. Krupa et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells

(2010) Amit K. Pandey et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes

(2009) Michael Mauer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET